original ) (raw )Pancreatic Safety of Sitagliptin in the TECOS Study
Julio Wainstein
Diabetes care, 2016
View PDFchevron_right
Saxagliptin-induced Recurrent Acute Pancreatitis
Meng Shun Sun
Internal Medicine, 2014
View PDFchevron_right
Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials
Ilaria Dicembrini
Diabetes Research and Clinical Practice, 2020
View PDFchevron_right
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
William Chen
Diabetes Care, 2010
View PDFchevron_right
Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies
Ileana Baldi
Endocrine, 2014
View PDFchevron_right
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Michael Paterson
JAMA internal medicine, 2016
View PDFchevron_right
Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study
Carmen Serban
Endocrinology, Diabetes & Metabolism, 2019
View PDFchevron_right
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
D. Funch
Diabetes, Obesity and Metabolism, 2014
View PDFchevron_right
Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study
Lee-Ming Chuang
Medicine, 2016
View PDFchevron_right
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study
Zuoyi Zhang
2013
View PDFchevron_right
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
Robert Frederich
Diabetology and Metabolic Syndrome
View PDFchevron_right
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kausik Ray
New England Journal of Medicine, 2013
View PDFchevron_right
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Carlos Saboya
Gastroenterology, 2009
View PDFchevron_right
Sitagliptin Associated Pancreatic Carcinoma: a Review of the FDA AERS Database
Robbert P. van Manen
2014
View PDFchevron_right
Pancreatitis-Diabetes-Pancreatic Cancer
Jill Smith
Pancreas, 2013
View PDFchevron_right
Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium
Ersilia Lucenteforte , Anthony Miller
Annals of Oncology, 2014
View PDFchevron_right
Diabetes mellitus, other medical conditions and pancreatic cancer: a case-control study
Marie Swanson
Diabetes/Metabolism Research and Reviews, 2011
View PDFchevron_right
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
German Malaga
BMJ (Clinical research ed.), 2014
View PDFchevron_right
Clinical and Biological Data in Patients with Pancreatic Cancer vs. Chronic Pancreatitis—A Single Center Comparative Analysis
Camelia Diaconu
Diagnostics
View PDFchevron_right
Association Between Pancreatitis and Subsequent Risk of Pancreatic Cancer: a Systematic Review of Epidemiological Studies
jing chai
Asian Pacific Journal of Cancer Prevention, 2014
View PDFchevron_right
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
Jasmine Gonzalvo
Clinical Therapeutics, 2011
View PDFchevron_right
Acute Pancreatitis in Association With Type 2 Diabetes and Antidiabetic Drugs: A population-based cohort study
Luis Rodríguez
Diabetes Care, 2010
View PDFchevron_right
The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study
Amit Garg
CMAJ open
View PDFchevron_right
Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials
Edwin Gale
Diabetes Care, 2015
View PDFchevron_right
Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: Comparison of DPP-4 inhibitors with other oral anti-diabetic drugs
Daisuke Yabe
View PDFchevron_right
PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
Sudhir Srivastava
Pancreas
View PDFchevron_right
Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival
Audrius Dulskas
International Journal of Environmental Research and Public Health, 2020
View PDFchevron_right
Lipid-Modifying Therapies and Risk of Pancreatitis
John Kjekshus
JAMA, 2012
View PDFchevron_right
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies
Hanieh Razzaghi
Pharmacoepidemiology and Drug Safety, 2012
View PDFchevron_right
The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session
Pablo Aschner
Diabetology & Metabolic Syndrome, 2010
View PDFchevron_right